ATS 2020 Advance Program

11:15 Pro/Con Debate: Treatment of Mycobacterium Abscessus Infection J. Philley, MD, Tyler, TX D.E. Griffith, MD, Tyler, TX 11:45 Questions and Answers 12:00 LUNCH 1:00 Inflammation in Bronchiectasis J.D. Chalmers, MD, PhD, Dundee, United Kingdom 1:30 Immunology of Bronchiectasis and Pulmonary Nontuberculous Mycobacteria K.N. Olivier, MD, MPH, ATSF, Bethesda, MD 2:00 The Microbiome in Pulmonary NTM I. Sulaiman, MD, Dublin, Ireland 2:30 Questions and Answers 2:45 Break 3:00 Case Based Panel Discussion P.J. McShane, MD, Chicago, IL A. Basavaraj, MD, ATSF, New York, NY S.H. Kasperbauer, MD, Denver, CO BASIC • CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE PG11 PULMONARY HYPERTENSION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A CLOSER LOOK AT THE LEFT HEART Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 Assembly on Pulmonary Circulation 8:00 a.m. - 4:00 p.m. Target Audience Basic scientists, residents, fellows, pulmonologists, nurse practitioners, physician assistants, cardiologists, early career professionals, nurses Objectives At the conclusion of this session, the participant will be able to: • improve recognition and diagnosis of pulmonary hypertension associated with heart failure with preserved ejection fraction; • review the evidence for the use of pulmonary vasodilator therapy and avoid misuse of non-evidence based therapies for patients with PH-HFpEF; • review ongoing clinical trials in PH-HFpEF and novel potential therapeutic targets in PH-HFpEF. Pulmonary hypertension due to left heart disease (Group 2 PH) is the most prevalent form of PH worldwide. 12-13% of Group 2 PH patients display pulmonary arterial remodeling and are associated with poor prognosis, imposing an economic burden of about 8 billion dollars per annum. Despite increasing interest and a growing number of related publications, no approved specific medication or consensus therapeutic strategy for Group 2 PH is available at present. In this course, we want the audience to learn about current developments in Group 2 PH, from bench to bedside, focusing on pathogenesis, clinical phenotypes, diagnostic factors, clinical trial updates and future perspectives. Chairing: N. Al-Naamani, MD, MS, Philadelphia, PA Y.C. Lai, PhD, Indianapolis, IN J.A. Mazurek, MD, Philadelphia, PA 8:00 The Pathogenesis and Epidemiology of PH-HFpEF J.A. Mazurek, MD, Philadelphia, PA 8:40 Diagnostic Role of Exercise and Dynamic Challenge in PH-HFpEF A.B. Waxman, MD, PhD, Boston, MA 9:20 Look into My Heart (and Lungs): RV Imaging in PH-HpEF R.R. Vanderpool, BS, MS, PhD, Tucson, AZ 10:00 Biomarkers in PH-HFpEF Y.C. Lai, PhD, Indianapolis, IN 10:20 Break 10:35 Myocardial and Vascular Stiffness in PH-HFpEF I.M. Lang, MD, Vienna, Austria ATS 2020 • Philadelphia, PA 12 FRIDAY • MAY 15